KOSDAQCosmetics260930

CTK

₩1,712▼ 1.44%2026-11-18 close
Market Cap
₩33.1B
Turnover
₩7,891,782
Volume
4.6K
Shares out.
19.3M
PER
—
PBR
0.2×
EPS
-₩609
Dividend Yield
5.75%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩100 per share · Prices as of the 2026-11-18 close

01

Report overview

CTK: Testing Whether Losses Keep Narrowing

CTK has posted net losses attributable to controlling shareholders for five consecutive quarters through the third quarter of 2026, although the operating and net loss sizes have narrowed on a quarterly basis.

  1. 1

    Revenue in 2025 was KRW 89.2 billion, the largest year in the 2022 to 2025 span, while the company swung to an operating loss of KRW 5.67 billion and a net loss attributable to controlling shareholders of KRW 7.02 billion.

  2. 2

    Third-quarter 2026 revenue fell 21.2% year on year to KRW 24.5 billion, and the operating result returned to a KRW 2.85 billion loss after a small profit in the second quarter.

  3. 3

    The business runs on a turnkey model that relies on OEM and ODM partners rather than owned plants, with a heavy North American customer base.

  4. 4

    The debt-to-equity ratio rose to 75.5% at the end of 2025 from 22.1% a year earlier, and operating cash flow was negative in both 2024 and 2025.

  5. 5

    The price-to-book multiple sits well below 1x, so the gap between asset value and the pace of earnings recovery is the central question.

02

Business structure

CTK is a cosmetics platform company that bundles planning, manufacturing, fulfillment and logistics for beauty products on a turnkey basis. It runs without owned factories and produces through OEM and ODM partners, a structure cited for production flexibility.

A 2023 brokerage report put the 2022 revenue mix at cosmetics manufacturing 74.0%, logistics services 24.3% and brand services 1.7%. North America accounted for roughly 70% of revenue, and the customer list spans global brands and independent labels.

The 2024 segment table shows CTK CLIP at about 97% of sales, which suggests a change in reporting categories, so segment weights should be rechecked against the periodic filings.

Domestic listed ODM and OEM peers such as Kolmar Korea, Cosmax and Cosmecca Korea operate in the same industry, and the main structural difference is CTK's reliance on partner-owned production.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩31.1B-₩4.1B−13.0%
2025Q4₩16B-₩2.2B−13.8%
2026Q1₩24.5B-₩1.7B−7.1%
2026Q2₩29B₩500M1.6%
2026Q3₩24.5B-₩2.9B−11.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩69.4B-₩15.2B-₩17.7B−21.9%−11.5%18.3%
2023₩88.9B₩2.7B₩6.9B3.1%4.4%19.7%
2024₩83.6B₩100M-₩3.3B0.2%−2.1%22.1%
2025₩89.2B-₩5.7B-₩7B−6.4%−4.7%75.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue in the disclosed figures rose from KRW 69.4 billion in 2022 to KRW 88.9 billion in 2023 (up 28.2% year on year), dipped to KRW 83.6 billion in 2024 (down 6.0%), and reached KRW 89.2 billion in 2025 (up 6.7%).

The company attributed the 2025 growth to the consolidation of newly included subsidiaries and higher sales at major subsidiaries.

Operating profit swung from an operating loss of KRW 15.2 billion in 2022 to an operating profit of KRW 2.74 billion in 2023, then fell 95.1% to KRW 135 million in 2024 and turned into an operating loss of KRW 5.67 billion in 2025, with an operating margin of -6.4%.

Net income attributable to controlling shareholders moved from a KRW 6.94 billion profit in 2023 to losses of KRW 3.27 billion in 2024 and KRW 7.02 billion in 2025. Total net income including non-controlling interests was a loss of KRW 7.33 billion in 2025, a different figure from the controlling-shareholder line.

Quarterly revenue was KRW 31.1 billion in the third quarter of 2025, KRW 16 billion in the fourth quarter, KRW 24.5 billion in the first quarter of 2026, KRW 29 billion in the second quarter and KRW 24.5 billion in the third quarter.

The second quarter of 2026 produced an operating profit of KRW 469 million, while the third quarter reverted to an operating loss of KRW 2.85 billion.

Cumulative revenue for the first three quarters of 2026 was KRW 77.9 billion, up 6.4%, while cumulative operating loss widened to KRW 4.13 billion, according to preliminary results published on November 10, 2026 that remain subject to audit review. Net losses attributable to controlling shareholders over the last four quarters totaled KRW 11.8 billion.

05

Industry analysis

The cosmetics ODM and OEM market moves with global brands outsourcing production and with the growth of independent labels. CTK is a turnkey supplier with a heavy North American customer mix and, unlike larger domestic ODM peers, keeps little owned production capacity.

That structure lowers capex needs but makes margins depend on partners' quality and cost control. A 2024 brokerage view tied the limits on profitability to continued losses in the eco-friendly business and capacity spending on a North American OTC plant.

That assessment dates from 2024, and later segment results should be checked in the periodic filings. Demand from global brands is sensitive to U.S. and European consumption, exchange rates and customer inventory decisions.

Quarterly revenue swings, including a 48.7% quarter-on-quarter drop in the fourth quarter of 2025 followed by a 53.2% rebound in the first quarter of 2026, point to order timing volatility.

Compared with domestic listed peers such as Cosmax, Kolmar Korea and Cosmecca Korea, customer concentration and quarterly variability are the key comparison points.

06

Outlook

When the company disclosed its 2025 results, it said the restructuring of its business had been completed and expected a full-scale growth recovery in 2026. The 2026 outcome has not yet confirmed that expectation.

Cumulative revenue for the first three quarters of 2026 rose, but the cumulative operating loss widened and third-quarter revenue fell year on year. A 2024 brokerage report cited the start-up of a North American OTC plant and growth in biodegradable plastics as key variables.

That plant timing was described for 2024, and how it affected later revenue and costs is not detailed in the disclosed figures. The items to verify are whether full-year 2026 operating results return to profit and whether fourth-quarter 2026 revenue recovers from the third quarter.

Since the third-quarter 2026 figures are preliminary, the final results need to confirm whether the narrowing of the operating loss holds.

07

Valuation

PER
—
PBR
0.2×
ROE
-8.1%
EPS
-₩609
BPS
₩7,353
Dividend per share
₩100

CTK's valuation reads as a comparison between its market price and its book value on one side and its current earnings base on the other. The price-to-book multiple sits well below 1x, meaning the market values the company at a low level relative to book equity.

Because net losses have continued over the last four quarters, a price-to-earnings multiple cannot be calculated. Asset-based and dividend-based views therefore carry more weight than earnings multiples. The dividend yield should be read alongside operating cash flow, which was negative in both 2024 and 2025.

Net income attributable to controlling shareholders was positive in 2023, which marks a earnings level the company has reached before and serves as a reference point for the current loss period.

The debt-to-equity ratio rose to 75.5% at the end of 2025, which affects how a low price-to-book reading should be interpreted. The gap between book value and market value is narrow to explain without knowing whether earnings recover.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Narrowing quarterly losses

Third-quarter 2026 operating loss narrowed year on year, and the second quarter of 2026 returned to an operating profit of KRW 469 million.

Net loss attributable to controlling shareholders shrank from KRW 4.59 billion in the third quarter of 2025 to KRW 1.9 billion in the third quarter of 2026, a trend that can be read as an early sign of recovery.

Restructuring and consolidation effects

The company attributed 2025 revenue growth to newly consolidated subsidiaries and higher sales at major subsidiaries. At KRW 89.2 billion, 2025 revenue was the largest of the 2022 to 2025 period, and if the restructuring carries into 2026 results, the broader revenue base could be a lasting gain.

Global customer base and turnkey model

CTK serves global brands such as L'Oréal, Unilever and Estée Lauder alongside independent labels. Its partner-based production limits fixed capital spending, and the North American OTC plant, if it runs as planned, is cited as a route to higher-value product lines.

09

Bear factors

Two straight loss years and negative operating cash flow

Net loss attributable to controlling shareholders was KRW 3.27 billion in 2024 and KRW 7.02 billion in 2025, two consecutive loss years. Operating cash flow was negative at KRW 7.2 billion in 2024 and KRW 8.25 billion in 2025, and the annual filings do not yet show a return to cash generation.

Third-quarter revenue decline and renewed operating loss

Third-quarter 2026 revenue fell 21.2% year on year to KRW 24.5 billion. After a second-quarter operating profit, the third quarter reverted to an operating loss of KRW 2.85 billion, and cumulative net loss for the first three quarters widened 134.7% in preliminary disclosures.

Rising debt burden

The debt-to-equity ratio rose from 22.1% at the end of 2024 to 75.5% at the end of 2025. Total liabilities of KRW 110.5 billion are large relative to total equity of KRW 146.3 billion, and with losses continuing, the balance sheet has less room to absorb further shocks.

10

Risk factors

Customer and regional concentration

North America accounts for roughly 70% of revenue, so results depend heavily on U.S. consumption and on the purchasing decisions of key customers. Inventory cuts or lower orders from global brands can move quarterly revenue sharply, as the 48.7% quarter-on-quarter drop in the fourth quarter of 2025 showed.

Preliminary figures before audit

The third-quarter 2026 results and the first-nine-month totals were disclosed as preliminary and may change after external audit or review. Profit and loss figures could shift during the finalization of periodic filings, especially items such as the cumulative net loss increase.

Financial capacity and liquidity

Market capitalization is around KRW 33.7 billion, which places CTK among small caps, and operating cash flow has been negative for two years. Rising debt combined with losses could increase the need for additional funding, and small-cap shares can also show thin trading and larger price swings.

11

What to watch next

  1. Late January to mid-February 2027 (typical timing)

    Check whether the full-year 2026 preliminary results show an operating profit and whether fourth-quarter revenue recovers from the third quarter. The direction of full-year operating results will anchor the reading of later periodic filings.

  2. End of March 2027

    The 2026 annual business report deadline, when segment revenue, regional mix, cash flow and debt structure are finalized. The differences from preliminary figures and the direction of operating cash flow are the points to verify.

  3. Around May 15, 2027

    The deadline for the first-quarter 2027 quarterly report. Beyond the full-year direction, it will show whether quarterly operating margin stays positive and whether the North American OTC capacity appears in the revenue mix.

12

Overall view

CTK's revenue reached KRW 89.2 billion in 2025, but continued operating and net losses mean its earnings base has not yet recovered. Third-quarter 2026 revenue fell 21.2% year on year, and an operating profit in the second quarter reverted to an operating loss in the third.

Net loss attributable to controlling shareholders did shrink from KRW 4.59 billion in the third quarter of 2025 to KRW 1.9 billion in the third quarter of 2026, so the quarterly narrowing is visible.

Bullish points include the restructuring and consolidation effects, the global customer base and the low capital needs of a turnkey model. Bearish points include two straight loss years, negative operating cash flow, a debt-to-equity ratio that rose to 75.5% and concentration in North America.

The price-to-book multiple sits well below 1x, while no earnings multiple can be calculated. The next points to verify are the direction of full-year 2026 operating results and the cash flow structure in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. ssl.pstatic.net
  2. vegannews.co.kr
  3. kr.acrofan.com
  4. ssl.pstatic.net
  5. comp.fnguide.com
  6. comp.fnguide.com
  7. m.thinkpool.com
  8. asp01.fnguide.com
  9. digitaltoday.co.kr
  10. vegannews.co.kr
  11. digitaltoday.co.kr
  12. tradingkey.com
  13. kr.investing.com
  14. tradingkey.com
  15. kr.investing.com
  16. kr.investing.com
  17. dailyinvest.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis